132 results about "Reperfusion Damages" patented technology

Methods and compositions are disclosed that are useful for the prevention and/or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic/reperfusion damage in humans; and cardiovascular trauma. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that interfere with the production and/or biological activities of sphingolipids and their metabolites, particularly sphingosine (SPH) and sphingosine-1-phosphate (S-1-P). Also disclosed are methods for identifying and isolating therapeutic agents.

The current invention provides a new organ preservation solution, suitable for machine perfusion, for maintaining viability of organs, parts of organs and tissues. This solution has been designed to overcome a number of problems associated with hypothermic machine perfusion of donor organs, in particular organs obtained from non-heart-beating donors. The solution prevents or minimizes the adverse affects caused by ischemia, hypoxia, energy and nutrient depletion, acidification, hypothermia and reperfusion injury. The preservation solutions according to the current invention are superior to current state of the art preservation solutions, in particular for preservation and perfusion of organs obtained from non-heart-bearing donors, by supplying increased concentrations and an optimized balance of amino acids, vitamins, anti-oxidants, high molecular weight additives and enhanced buffering capacity. In addition, the preservation solution according to the invention combines optimal physical and chemical properties with the use of readily available, inexpensive and pharmaceutically tested and acceptable compounds, reducing the cost of manufacturing and facilitating medical certification of solutions according to the current invention.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

The invention relates to 24(R)-pseudoginsenoside-GQ as well as a semisynthesis method and medicinal application thereof, belonging to a new compound as well as a synthesis method and medicinal application thereof. In the invention, 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3 is used as a raw material, and under an acid condition, a new compound is synthesized through the steps of oxidization, cyclization, and the like, wherein the chemical name of the new compound is 3-O-[beta-D-glucopyranose-(1-2)-beta-D-glucopyranose group]-damma-20S, 24R-epoxy-3beta, 12beta, 25-triol being short for 24(R)-pseudoginsenoside-GQ, the productivity of which reaches higher than 80 percent. The 24(R)-pseudoginsenoside-GQ has wide medicinal application in preparing medicaments for treating coronary heart diseases, myocardial ischemia, ischemic shocks, arrhythmia and reperfusion damages and resisting cancer.

The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A_2A adenosine receptors (ARs).

The invention provides an intracranial hemorrhage transformation model after acute cerebral ischemia mechanical recanalization and a microRNA screening method and application thereof. The intracranialhemorrhage transformation model after acute cerebral ischemia mechanical recanalization is established by using a hyperglycemia combined suture-occluded method MCA for occlusion for 5 hours and thenrecanalization for 19 hours. The intracranial hemorrhage transformation model has 33 microRNAs expressions with significant difference. A new method for the study of intracranial hemorrhage transformation after acute cerebral ischemia mechanical recanalization, and an innovative means for the diagnosis and treatment of reperfusion injury after endovascular interventional recanalization in acute ischemic stroke is provided.

The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.

The invention discloses a compound as shown in the structural general formula (I), wherein R is a substituent or double substituents and is independently selected from NO2, OH, OCH3, halogen and H. The compound is used for treating ischemia reperfusion injury. The compound is simple and convenient in synthesis method; and a molecule of the compound contains a structural unit of the free radical of nitroxide to ensure that free radical can be removed efficiently and circularly, and the compound has a remarkable inhibiting effect on ischemia reperfusion injury, so that the compound has important practical values.

The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.

The present disclosure provides methods and compositions for treating coronary tissue damaged as a result of a cardiac disorder such as ischemia, acute myocardial infarction, vulnerable plaques, or reperfusion injury. Specifically, the cardiac disorder is treated using a multivalent molecule that is specific for a marker located, in or near the damaged coronary tissue and a marker located on a target cell (e.g., a stem cell). The multivalent molecule may be administered by intravenous injection, intra-arterial catheter, intramyocardial injection, or implantable device (e.g, stent).